Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
SAN MATEO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Navigator Medicines Inc., a clinical-stage biotech company pioneering best-in-class bispecific antibodies (bsAb) for inflammatory disorders and autoimmune diseases in areas of high unmet need, today announced rapid progress and new data from across its bsAb developm…
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)
- China Telecom Unveils TeleOCR: Lightweight 1.2B Model Tops Global Document Parsing Benchmarks
- Alpha Longevity Management Rebrands as Alpha Growth Management (Bermuda) Ltd; Establishes Representative Office in Japan
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →